Everest Medicines (SEHK:1952) anticipates a 37.2% annual revenue growth driven by EVER001 introduction. Challenges include unprofitability and cost management issues.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Everest Medicines (SEHK:1952) anticipates a 37.2% annual revenue growth driven by EVER001 introduction. Challenges include unprofitability and cost management issues.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing